Fernando Magdaleno
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Ablation of secreted phosphoprotein-1 in hepatocytes increases fatty acid oxidation and ameliorates alcohol-associated liver disease.
Journal: Alcohol, clinical & experimental research
Published: October 04, 2023
Intestinal Osteopontin Protects From Alcohol-induced Liver Injury by Preserving the Gut Microbiome and the Intestinal Barrier Function.
Journal: Cellular and molecular gastroenterology and hepatology
Published: March 08, 2022
The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.
Journal: Frontiers in molecular biosciences
Published: May 27, 2021
Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: June 03, 2020
Combination of CCl4 with alcoholic and metabolic injuries mimics human liver fibrosis.
Journal: American journal of physiology. Gastrointestinal and liver physiology
Published: June 13, 2019
Aminoguanidine reduces diabetes-associated cardiac fibrosis.
Journal: Experimental and therapeutic medicine
Published: January 30, 2019
Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis.
Journal: Frontiers in immunology
Published: October 30, 2018
TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor.
Journal: Scientific reports
Published: October 05, 2018
Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats.
Journal: Scientific reports
Published: September 10, 2018
Last Updated: 09/26/2026